EAM Investors’s Terns Pharmaceuticals TERN Stock Holding History

EAM Investors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.21M	Sell	98,860 -10,126	-9%	-$416K	0.6%	44
2025 Q4	$4.4M	Buy	+108,986	New	+$2.52M	0.49%	97
2023 Q2	–	Sell	-128,186	Closed	-$1.52M	–	365
2023 Q1	$1.52M	Hold	128,186	–	–	0.3%	168
2022 Q4	$1.3M	Buy	+128,186	New	+$853K	0.27%	175

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

EAM Investors's TERN Position: Q1 2026 in Review

EAM Investors reduced its Terns Pharmaceuticals (TERN) stake by 9.3% in Q1 2026, selling an estimated $416K and leaving 98,860 shares worth $5.21M. The position accounts for 0.6% of the portfolio, ranked #44.

EAM Investors first reported a position in TERN in Q4 2022 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

EAM Investors held 98,860 shares of Terns Pharmaceuticals worth $5.21M as of Q1 2026.
EAM Investors sold 10,126 Terns Pharmaceuticals shares in Q1 2026, an estimated $416K.
Terns Pharmaceuticals made up 0.6% of EAM Investors's portfolio in Q1 2026, its #44 holding.
EAM Investors first reported a position in Terns Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.